Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

RA Chem Pharma

Request full access

Ra chem pharma limited and their merger with cohance lifesciences limited

Hyderabad, IndiaFounded 2003

About RA Chem Pharma

RA Chem Pharma Limited operates as a vertically integrated pharmaceutical entity based in Hyderabad, India, primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), finished dosage forms (FDF), and providing clinical research services. The company was founded in 2003 by J. Rajender Rao, Ravi K. Yerra, Sirish Kumar, and B. Srinivasa Reddy, who brought together their collective experience from different domains to establish the firm. Some records indicate an earlier incorporation date of 1996.

The company's business is structured across three main verticals: API and Intermediates, Formulations, and Clinical Research. This integrated model allows it to offer end-to-end services to its global client base, which includes major pharmaceutical companies in India and more than 40 other countries. The API division focuses on producing niche active ingredients and intermediates under cGMP conditions. The formulations division is a contract development and manufacturing partner for international clients, specializing in solid dosage forms like tablets and capsules with immediate and modified release mechanisms. Its clinical research and biosciences division conducts bioequivalence and bioavailability studies for a global clientele.

Historically, RA Chem Pharma has demonstrated significant growth. After being founded, it achieved substantial operational scale within a decade. A significant milestone occurred in 2017 when Micro Labs acquired a majority stake in the company. Subsequently, in July 2020, global private equity firm Advent International signed an agreement to acquire a controlling stake from Micro Labs, valuing the company at approximately ₹1,000 crore. This acquisition was part of Advent's strategy to build a leading API platform in India. Following this, in November 2022, RA Chem Pharma was amalgamated with its holding company and renamed Cohance Lifesciences Limited.

The company's manufacturing and research facilities hold multiple international accreditations, including approvals from the USFDA, UKMHRA, EMEA (Europe), and others. Its product portfolio is diverse, covering various therapeutic areas such as anti-depressants, anti-spasmodics, and anti-fungals, and also extends into niche markets like animal health and cosmeceuticals. The company serves both innovator and generic pharmaceutical players globally, leveraging a strong pipeline of Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) to penetrate regulated markets.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
375
Open positions
None listed
Dealroom signal
25.2/100

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
BUYOUT✓Exit Jul 2020 $134M $134M Advent International —
EARLY VCEquity / VC Apr 2017 $11M $44M Undisclosed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

RA Chem Pharma website traffic

Latest recorded traffic for RA Chem Pharma is 650 monthly website visits, up 10.2% over the last three months. RA Chem Pharma's team declined 3.1% over the past year.

Latest monthly visits650 3-month web change+10.2% 1-year team growth-3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

RA Chem Pharma in the Hyderabad ecosystem

Live from Dealroom

The RA Chem Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Advent International
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇮🇳 India97.7%
🇮🇪 Ireland1.1%
🇦🇪 United Arab Emirates1.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about RA Chem Pharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See RA Chem Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.